Federal Judge Lets Stand $6.4 Billion Suit Claiming BMS Stalled New CAR T Cell Therapy
A federal judge is letting stand a $6.4 billion claim that Bristol Myers Squibb stalled its CAR T cell therapy Breyanzi (lisocabtagene maraleucel) from getting to the market in order to duck out of making payments to shareholders of Celgene, which it bought three years ago.
During the Celgene acquisition, BMS said it would pay Celgene stockholders an additional $9 per share if it got FDA approval by certain deadlines for Breyanzi and two other drugs developed by Celgene.
On June 24, the FDA approved Breyanzi for several large B-cell lymphoma (LBCL) indications in adults, making it the CAR T cell therapy with the broadest patient eligibility in relapsed or refractory LBCL.
June 28, 2022
